期刊文献+

雷贝拉唑三联疗法治疗幽门螺杆菌阳性十二指肠溃疡疗效观察 被引量:6

下载PDF
导出
摘要 目的观察雷贝拉唑+阿莫西林+左氧氟沙星三联疗法治疗幽门螺杆菌(H.pylori)阳性十二指肠球部溃疡患者的临床疗效、H.pylori根除率、不良反应和2 a溃疡复发率。方法采用前瞻随机对照方法,将符合条件的98例H.pylori阳性十二指肠球部溃疡患者随机分为2组:研究组口服雷贝拉唑10 mg+阿莫西林1 g+左氧氟沙星200mg,每日2次,共1周,然后每天再服用雷贝拉唑10 mg,用药1周;对照组口服奥美拉唑20 mg+阿莫西林1 g+克拉霉素500 mg,每日2次,共1周,然后每天再服用奥美拉唑20 mg,用药1周。停药4周后复查,观察临床缓解率、H.py-lori根除率、镜下溃疡愈合率和不良反应。于治疗后2 a行内镜复查,观察溃疡复发率。结果共有93例入选者完成治疗和随访,研究组46例,对照组47例。2组在停药4周复诊时临床症状缓解率研究组为78%,显著高于对照组的51%(P<0.01);H.pylori根除率、镜下溃疡愈合率研究组分别为91%和94%,高于对照组的72%和79%(P均<0.05);而不良反应发生率和2 a随访溃疡复发率2组无显著性差异。结论对H.pylori阳性的十二指肠溃疡,雷贝拉唑联合左氧氟沙星、阿莫西林三联疗法效果较好,是安全、有效、适合本地区较好的一线治疗方案。
作者 梁凯 王飞
出处 《现代中西医结合杂志》 CAS 2009年第35期4355-4357,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献7

  • 1Besancon M,Simon A,Sachs G, et al. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents[J]. J Biol Chem,1997,272(22) :438-446.
  • 2Hirai M, Azuma T, l to S, et al, A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori[J]. J Gastroenterol, 1995,30(4) :61 - 64.
  • 3Hokari K, Sugiyama T, Kato M, et al. Efficacy of triple therapy with raheprazole for Helicohacter pylori infection and CYP2C19 genetic polymorphisism [ J ]. Aliment Phar macol Ther, 2001, 15 (14) :79- 84.
  • 4Malfertheiner P, Megraud F, O' Morain C, et al. Current concepts in the management of Helicobacter pylori infection:the Maastrieht 2- 2000 Consensus Report [ J ]. Aliment Pharmaeol Ther, 2002, 16 (2):167- 180.
  • 5Murakami K, Kimoto M. Antibiotic resistant H. pylori strains in the last ten years in Japan[J]. Nippon Rinsho,1999,57(5):81 -86.
  • 6邹军,杨昭徐,覃卓明.左旋氧氟沙星抗幽门螺杆菌的实验室评价和临床研究[J].中华医学杂志,2003,83(20):1778-1781. 被引量:87
  • 7胡伏莲,胡品津,刘文忠,王继德,吕农华,萧树东,张万岱,成虹,谢勇.第三次全国幽门螺杆菌感染若干问题共识报告(2007·庐山)[J].现代消化及介入诊疗,2008,13(1):73-76. 被引量:104

二级参考文献22

  • 1黄跃,许鲁宁.环丙沙星一周疗法根除幽门螺杆菌[J].中国新药杂志,1994,3(2):34-36. 被引量:10
  • 2中国慢性胃炎共识意见[J].胃肠病学,2006,11(11):674-684. 被引量:835
  • 3Van der Hulst RWM, Keller JJ, Rauws EAJ, et al. Theatment of Helicobacter pylori infection: a review of the world literature. Helicobacter, 1996,1:6-19.
  • 4Georgopoulos SD, Ladas SD, Karatapanis S, et al. Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin, and clarithromycin. Dig Dis Sci,2000 ,45:63-67.
  • 5Piccolomini R, Bonaventura G, Catamo G, et al. Comparative evaluation of the E test, agar dilution, and broth microdilution for testing susceptibilities of Helicobacter pylori strains to 20 antimicrobial agents. J Clin Microbiol,1997,35:1842-1844.
  • 6Pfaller MA, Barry AL, Fuchs PC, et al. Levofloxacin disk potency and tentative interpretive criteria for susceptibility tests. J Clin Microbiol,1993, 31:1924-1926.
  • 7Sharma VK, Vasudeva R, Howden CW. A national survey of gastroenterologists' current opinions and practices related to Hp. Am J Gastroenterol,1998,93:1647-1657.
  • 8Franzin L, Pennazio M, Cabodi D, et al. Clarithromycin and amoxicillin susceptibility of Helicobacter pylori strains isolated from adult patients with gastric or duodenal ulcer in Italy. Curr Microbiol, 2000,40:96-100.
  • 9Ducons JA, Santolaria S, Guirao R, et al. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a porospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. Aliment Pharmacol Ther, 1999,13:775-780.
  • 10Yakoob J, Fan XG, Hu GL, et al. Antibiotic susceptibility of Helicobacter pylori in the chinese population. J Gastroenterol Hepatol, 2001,16:981-985.

共引文献188

同被引文献47

引证文献6

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部